/PROK
PROK Stock - ProKidney Corp.
Healthcare|BiotechnologyNASDAQ
$2.37-4.05%
$0.10 (-4.05%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.61
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.47
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+195.4%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PROK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.35 – $2.39
TARGET (TP)$7.00
STOP LOSS$2.18
RISK/REWARD1:24.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.82
52W High$7.13
52W Low$0.46
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $76,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $76,000 | N/A | N/A | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-183,676,000 | $-151,522,000 | $-153,007,000 | $-55,110,000 | $-27,024,000 |
| Net Income | $-61,186,000 | $-35,468,000 | $-108,032,000 | $-55,146,000 | $-26,749,000 |
| Net Margin | -80507.9% | N/A | N/A | N/A | N/A |
| EPS | $-0.62 | $-0.57 | $-1.76 | $-1.73 | $-0.14 |
Company Overview
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
62%
Hold / Neutral
4
31%
Sell / Underperform
1
8%
Analyst Consensus🟡 Mixed
8 Bullish5 Neutral/Bearish
Price Targets
$11
Average Target
↑ 381.0% Upside
Now
$1
Low
$11
Average
$18
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | H.C. Wainwright | Initiation | Buy | $12 |
| June 30th 2025 | BofA Securities | Downgrade | Underperform | $1 |
| September 30th 2024 | JP Morgan | Initiation | Neutral | - |
| September 10th 2024 | Guggenheim | Initiation | Buy | $6 |
| March 7th 2024 | Morgan Stanley | Resumed | Equal Weight | $3 |
| January 2nd 2024 | BofA Securities | Downgrade | Neutral | - |
| July 25th 2023 | BTIG Research | Initiation | Buy | $16 |
| December 21st 2022 | Jefferies | Initiation | Buy | $15 |
| November 10th 2022 | Morgan Stanley | Initiation | Equal Weight | $13 |
| October 18th 2022 | UBS | Initiation | Buy | $18 |
| October 14th 2022 | Citigroup | Initiation | Buy | $16 |
| September 23rd 2022 | BofA Securities | Initiation | Buy | $14 |
| September 2nd 2022 | Evercore ISI | Initiation | Outperform | - |
Earnings History & Surprises
PROKBeat Rate
69%
Last 13 quarters
Avg Surprise
+9.5%
EPS vs Estimate
Beats / Misses
9/2
2 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
+52.6%
$-0.09vs$-0.19
Q2 24
+36.0%
$-0.16vs$-0.25
Q3 24
+5.9%
$-0.16vs$-0.17
Q4 24
0.0%
$-0.14vs$-0.14
Q1 25
-21.4%
$-0.17vs$-0.14
Q2 25
+18.8%
$-0.13vs$-0.16
Q3 25
+7.1%
$-0.13vs$-0.14
Q4 25
0.0%
$-0.12vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.12 | $-0.12 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.14 | $-0.13 | +7.1% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.14 | $-0.14 | 0.0% | = MET |
Q3 2024 | Aug 9, 2024 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-0.25 | $-0.16 | +36.0% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.19 | $-0.09 | +52.6% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.41 | $-0.14 | +65.9% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.39 | $-0.16 | +59.0% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-0.24 | $-0.11 | +54.2% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.05 | $-0.13 | -160.0% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | — | $-0.36 | — | — |
Q2 2022 | May 16, 2022 | — | $-2.12 | — | — |
Q1 2022 | Mar 24, 2022 | — | $-0.43 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.54 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.40 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.36 | — | — |
Latest News
HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12
📈 PositiveBenzinga•Dec 16, 2025, 12:03 PM
ProKidney GAAP EPS of -$0.12 beats by $0.02, revenue of $0.22M beats by $0.18M
📈 PositiveSeeking Alpha•Nov 10, 2025, 10:01 PM
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:36 PM
ProKidney To Present LAte-Breaking Poster On Phase 2 REGEN-007 Trial Results At American Society of Nephrology's Kidney Week
📈 PositiveBenzinga•Oct 20, 2025, 11:43 AM
ProKidney Corp. Signs New $19.1M Agreement To Sell Greensboro, NC Property After Prior Deal Termination
➖ NeutralBenzinga•Oct 17, 2025, 08:41 PM
ProKidney Reports 78 Percent Gain in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 02:04 AM
ProKidney, FDA align on accelerated approval pathway for Rilparencel
📈 PositiveSeeking Alpha•Jul 15, 2025, 01:44 PM
ProKidney spikes after mid-stage trial data for lead asset
📈 PositiveSeeking Alpha•Jul 8, 2025, 12:04 PM
Frequently Asked Questions about PROK
What is PROK's current stock price?
ProKidney Corp. (PROK) is currently trading at $2.37 per share. The stock has moved -4.05% today.
What is the analyst price target for PROK?
The average analyst price target for PROK is $7.00, based on 1 analyst.
What sector is ProKidney Corp. in?
ProKidney Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PROK's market cap?
ProKidney Corp. has a market capitalization of $0.67 billion, making it a small-cap company.
Does PROK pay dividends?
No, ProKidney Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to PROK for comparison